We may be looking at wrong mutation for breast cancer treatment

A leading gene candidate that has been the target of breast cancer drug development may not be as promising as initially thought, according to new research. Mutation in the gene PIK3CA is the second most prevalent gene mutation in breast cancer and is found in 20% of all breast cancers. This has led people to think these changes may be driving breast cancer. Yet these mutations are also known to be present in neoplastic lesions -pre-cancerous growths many of which are thought to be benign, that have not invaded the surrounding tissue, scientists say. —> Read More